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Abstract
Heparanase is an endoglycosidase that specifically
cleaves heparan sulfate (HS) side chains of heparan
sulfate proteoglycans, the major proteoglycan in the
extracellular matrix (ECM) and cell surfaces. Hepa-
ranase upregulation was documented in an increasing
number of primary human tumors, correlating with re-
duced postoperative survival rate and enhanced tumor
angiogenesis. The purpose of the current study was
to determine heparanase levels in blood samples col-
lected from pediatric cancer patients using an ELISA
method. Heparanase levels were elevated four-fold in
the plasma of cancer patients compared with healthy
controls (664 ± 143 vs 163 ± 18 pg/ml, respectively).
Evaluating plasma samples following anticancer ther-
apy revealed reduced heparanase levels (664 ± 143 vs
429 ± 82 pg/ml), differences that are statistically highly
significant (P = .0048). Of the 55 patients with com-
plete remission (CR) or very good partial remission
(VGPR) at restaging, 41 (74.5%) had lower heparanase
amounts, whereas 14 patients (25.5%) had similar or
higher amounts of plasma heparanase. All nine pa-
tients with stable or advancing disease had similar
or elevated levels of heparanase on restaging. The re-
sults show that heparanase levels are elevated in the
plasma of pediatric cancer patients and closely cor-
relate with treatment responsiveness, indicating that
heparanase levels can be used to diagnose and moni-
tor patient’s response to anticancer treatment.
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Introduction
Heparanase is an endo-b-glucuronidase that cleaves hepa-
ran sulfate (HS) side chains at a limited number of sites,
yielding HS fragments of still appreciable size (f 5–7 kDa)
[1–3]. Cleavage of HS, an important constituent of the extra-
cellular matrix (ECM) and basement membranes, is consid-
ered critical for cell invasion associated with inflammation,
angiogenesis, and tumor metastasis. This notion gained fur-
ther support by employing antisense, small interfering RNA, and
ribozyme technologies, clearly depicting heparanase-mediated
HS cleavage and ECM remodeling as critical requisites for
inflammation, angiogenesis, and metastatic spread [4–6]. Fur-
thermore, heparanase upregulation was documented in an in-
creasing number of primary human tumors, correlating with
enhanced local and distant metastasis, increased microvessel
density, and reduced postoperative survival of cancer patients
[7–9]. Collectively, these studies provide compelling evidence
for the clinical relevance of the enzyme, making it an attractive
target for the development of anticancer drugs [10,11]. Hepa-
ranase induction in human malignancies, as well as in several
other pathologies such as cirrhosis, nephrosis, and diabetes
[12–18], implies that the enzyme may serve as a valuable
marker for diagnosing the development of the diseases and,
possibly, to follow treatment efficiency. Recently, we reported
the development of an ELISA method capable of detection
and quantification of heparanase in urine samples and dem-
onstrated an elevation of heparanase levels in the urine of can-
cer and diabetes patients [19]. Here, we examined the ability
of the ELISA method to detect and quantify heparanase levels
in blood samples. We provide evidence that heparanase can
be quantified in plasma but not in serum samples. Heparanase
levels were significantly elevated in the plasma of pediatric
cancer patients and, moreover, correlated with therapy effec-
tiveness. These results indicate that heparanase levels can
be used to diagnose and monitor patient’s response to anti-
cancer treatments.
Abbreviations: CR, complete remission; ECM, extracellular matrix; ES, Ewing’s sarcoma;
HD, Hodgkin’s disease; HS, heparan sulfate; TP, tumor progression; VGPR, very good par-
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The study group consisted of 64 pediatric patients [19 pa-
tients with Hodgkin’s disease (HD), 11 with acute lympho-
blastic leukemia, 7 with osteosarcoma, 7 with non–Hodgkin
lymphoma, 4 each with brain glioma (2 with optic glioma and 2
with brain glioma), neuroblastoma, rhabdomyosarcoma, and
Ewing’s sarcoma (ES), and 1 each with Langerhan’s cell his-
tocytosis, germ cell tumor, Wilm’s tumor, nasopharynx carci-
noma, and glioblastoma multiform. Mean age was 10.3 years
(0.5–21), with 28 girls and 36 boys. This study was carried
out in accordance with Helsinki principles, with the approval
of the local Ethics Committee, and informed parental con-
sent. Children were diagnosed and treated in the Department
of Pediatric Hematology–Oncology at the Meyer Children’s
Hospital, Rambam Health Care Campus, Haifa, Israel.
Sample Collection
Blood samples were collected at diagnosis and at restaging
(i.e., after the first month of induction for leukemia patients;
two to three courses of chemotherapy for the other malignan-
cies) [20,21]. A total of 3 ml of peripheral blood was collected,
applying EDTA as an anticoagulant; samples were cooled and
plasma was obtained by centrifugation (1500g for 15 minutes
at 4jC). All samples were frozen and thawed once.
Antibodies and Reagents
Antiheparanase 1E1 monoclonal antibody and polyclonal
antibodies 1453 and 733 have been previously described
[19,22]. HRP-conjugated goat anti–rabbit antibody was pur-
chased from Jackson ImmunoResearch (West Grove, PA).
Microtiter 96-well plates (Maxisorp) were from Nunc (Roskilde,
Denmark). HRP colorimetric substrate 3,30,5,50-tetramethyl-
benzidine was purchased from Dako (Glostrup, Denmark).
Bovine serum albumin (BSA) was from MP Biomedicals
(Illkirch, France). Single-chain active heparanase (GS3) gene
construct was kindly provided by Dr. Christian Steinkuhler
(Instituto di Ricerche di Biologia Moleculare/Merck Research
Laboratories, Pomezia, Italy) [23], and the protein was puri-
fied from the conditioned medium of baculovirus-infected
insect cells, as described [23].
ELISA Method
The ELISA method was carried out as described [19].
Briefly, wells of microtiter plates were coated (for 18 hours
at 4jC) with 1 mg/ml 1E1 monoclonal antiheparanase anti-
body in 50 ml of coating buffer (0.05 M Na2CO3 and 0.05 M
NaHCO3, pH 9.6) and were then blocked with 1% BSA in
PBS for 1 hour at 37jC. Samples were diluted with 0.5%
BSA (1:1) and a total of 100 ml was loaded in duplicates and
incubated for 2 hours at room temperature, followed by the
addition of 100 ml antibody 1453 (1 mg/ml) for an additional
2 hours at room temperature. HRP-conjugated goat anti–
rabbit IgG (1:20,000) in blocking buffer was added (for 1 hour
at room temperature) and the reaction was visualized by the
addition of 100 ml of the chromogenic substrate (3,30,5,50-
tetramethylbenzidine) for 30 minutes. The reaction was
stopped with 100 ml H2SO4 and absorbance at 450 nm was
measured with a reduction at 630 nm using ELISA plate
reader. Plates were washed five times with washing buffer
(PBS, pH 7.4, containing 0.1% (v/v) Tween 20) after each
step. As a reference for quantification, a standard curve was
established by a serial dilution of recombinant single-chain
(GS3) active heparanase, ranging from 180 pg/ml to 5 ng/ml.
Immunohistochemistry
Staining of formalin-fixed, paraffin-embedded, 5-mm tissue
sections for heparanase was performed essentially as de-
scribed [22,24,25]. Briefly, slides were deparaffinized and re-
hydrated, and endogenous peroxidase activity was quenched
(for 30 minutes) by 3% hydrogen peroxide in methanol. Slides
were then subjected to antigen retrieval by boiling (for 20 min-
utes) in 10 mM citrate buffer, pH 6. Slides were incubated with
10% normal goat serum in PBS for 60 minutes to block non-
specific binding and were incubated (for 20 hours at 4jC) with
antiheparanase 733 antibody diluted 1:100 in blocking solution.
Slides were extensively washed with PBS containing 0.01%
Triton X-100 and incubated with a secondary reagent (Envision
Kit; Dako) according to the manufacturer’s instructions. Follow-
ing additional washes, color was developed with 3-amino-9-
ethylcarbazole reagent (Dako), and sections were counter-
stained with hematoxylin and mounted, as described [22,24,25].
Statistics
Data were analyzed using the Prism software (GraphPad,
San Diego, CA). One-tailed paired t-test and the nonpara-
metric Mann-Whitney test were employed. P < .05 was con-
sidered statistically significant.
Results
Detection and Quantification of Heparanase
in Blood Samples
We have recently developed an ELISA method capable of
detecting and quantifying heparanase in urine samples [19].
To expand the applications of our ELISA method, we evalu-
ated its ability to quantify heparanase levels in blood sam-
ples. Heparanase levels in serum of control donors were
found to be significantly higher than in plasma collected with
sodium citrate (1871 ± 116 vs 500 ± 29 pg/ml, respectively),
likely due to platelet activation and release of heparanase-
rich platelet dense granules [26,27] (Figure 1). Detection
of heparanase in plasma was also noted to be affected by
the anticoagulant employed, with lower levels quantified in
plasma collected with EDTA compared with sodium citrate
(163 ± 18 vs 500 ± 29 pg/ml, respectively; Figure 1). Be-
cause plasma collected with EDTA gave the lowest levels of
heparanase in control healthy donors, this procedure was
adopted for the rest of the study.
Detection and Quantification of Heparanase in Plasma
of Pediatric Cancer Patients
Encouraged by the ability of the ELISA method to quan-
tify heparanase in plasma, we next evaluated the level of
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heparanase in samples collected from pediatric cancer pa-
tients. Heparanase levels were elevated four-fold in the
plasma of cancer patients compared with healthy controls
(664 ± 143 vs 163 ± 18 pg/ml; Figure 2A). Evaluating plasma
samples following anticancer therapy revealed reduced hepa-
ranase levels (664 ± 143 vs 429 ± 82 pg/ml; Figure 2A),
differences that are statistically highly significant (P = .0048).
Plasma levels of heparanase as indicators of treatment ef-
fectiveness are further revealed by subgrouping the patients
according to who responded to the treatment and exhib-
ited complete remission (CR) or very good partial remission
(VGPR) and who did not respond well and showed tumor
progression (TP). Patients in CR or with VGPR had signifi-
cantly lower levels of heparanase at restaging (710 ± 162 vs
421 ± 91 pg/ml, respectively; Figure 2B). Moreover, whereas
the group that experienced disease remission exhibited re-
duced levels of heparanase (Figure 2B), patients with dis-
ease progression were diagnosed to bear a slight elevation
of heparanase levels (Figure 2C). Even more impressive
results were observed when heparanase levels were com-
pared for each patient individually at diagnosis and on re-
staging (Figure 2D). Of the 64 patients included, 45 (70.3%)
had lower amounts (at least 30% decrease) of heparanase
levels at restaging. Of these, 43 (95.6%) underwent CR. Of
the 64 patients, 19 (29.7%) had higher or equal amounts of
heparanase, and of these 7 (37%) exhibited stable disease
(SD) or TP, whereas the other 12 patients exhibited disease
remission (Table 1). Of the 55 patients with CR or VGPR
at restaging, 41 (74.5%) had lower heparanase amounts,
whereas 14 patients (25.5%) had similar or higher amounts
of plasma heparanase (Table 1). All 9 patients with stable or
advancing disease had similar or elevated levels of hepa-
ranase at restaging (Table 1). Interestingly, in a few cases
where an extended follow-up was available, heparanase
levels were noted to be further decreased, reaching its level
in control plasma (Figure 2E ). These results confirm the cor-
relation between treatment response and heparanase levels
in the plasma of pediatric cancer patients.
Heparanase Levels in HD
Because the study group available to us was heteroge-
neous and included a variety of hematological and solid
malignancies, we decided to confirm our findings in a more
homogenous group of patients. The largest group of patients
tested in the current study was HD (n = 19) (Table 2). The
average level of plasma heparanase in these patients was
1019 ± 334 pg/ml at diagnosis and 588 ± 173 pg/ml at re-
staging (Figure 3A), a decrease that is statistically significant
(P = .035). Remarkably, all 13 (68.4%) patients with lower
heparanase levels at restaging were at CR (Table 2). Of the
six patients with higher heparanase levels, three exhibited
stable disease or disease progression and showed modest
elevation of heparanase levels (Figure 3C). Heparanase
levels at diagnosis and restaging is shown for each individual
HD patient in Figure 3D. These results further emphasize
the correlation between response to treatment and hepara-
nase levels in the plasma of pediatric cancer patients.
Heparanase Expression By Sarcomas
Whereas upregulation of heparanase is well documented
in an increasing number of human carcinomas [8,9,11],
heparanase expression by sarcomas has not been reported
yet. Notably, heparanase was readily detected in the plasma
of sarcoma patients included in our study group (n = 15),
although heparanase elevation was modest (324 ± 44 pg/ml;
Table 3) in comparison to HD and no significant average
decrease was quantified following treatment (324 ± 44 vs
258 ± 65 pg/ml; Table 3). Plotting each patient individually
indicated however that, of the 13 patients who experienced
CR following treatment, 8 exhibited decreased levels of
heparanase (Figure 4). In addition, one of two patients who
underwent TP showed elevation of heparanase levels (Fig-
ure 4 and Table 3), suggesting that similar to HD, hepara-
nase levels closely reflect treatment responsiveness also in
sarcoma patients. To further confirm heparanase expres-
sion by sarcomas, paraffin-embedded sections of ES tumors
were stained with antiheparanase antibody. Positive stain-
ing of heparanase was observed in five of eight ES biopsy
specimens that were available to us, whereas three speci-
mens were negatively stained for heparanase (Figure 5A).
Heparanase staining was primarily evident in areas that ap-
pear to represent the invasive leading edge of the tumor
(Figure 5, B and C), in agreement with a similar staining
pattern observed in carcinomas [7]. Altogether our results
suggest that heparanase is upregulated in hematological
malignancies and solid tumors, including sarcomas, and that
Figure 1. Determination of heparanase levels in blood. Blood samples were
obtained from control healthy volunteers and allowed to clot to generate
serum (n = 20) or collected into tubes containing sodium citrate (n = 20) or
EDTA (n = 18) as anticoagulants to produce plasma. Samples were diluted
1:2 with PBS and heparanase levels were quantified by a sandwich ELISA
method, as described in the Materials and Methods section.
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Figure 2. Elevation of heparanase levels in the plasma of pediatric cancer patients. (A) Plasma samples were collected from 64 pediatric patients with various malignancies
at (n) diagnosis and ( ) restaging, following the recommended antitumor treatment, and heparanase levels were quantified by the ELISA method, as described above.
Average heparanase levels are also shown for the subgroups of patients that were diagnosed (B) to undergo CR or (C) to exhibit TP. (D) Representative heparanase levels
at (n) diagnosis and (5) restaging are shown individually for 21 patients. (E) For two HD and one acute lymphoblastic leukemia patients, plasma samples were available at
(n) diagnosis, ( ) restaging, and (5) follow-up. CR, complete remission; TP, tumor progression; VGPR, very good partial remission; SD, stable disease.
Table 1. Heparanase Levels in Pediatric Cancer Patients.
All Patients (N = 64) Heparanase
At Diagnosis (pg/ml) At Restaging (pg/ml) Normal (pg/ml)
Overall average 664 ± 143 429 ± 82 163 ± 18
P (diagnosis vs restaging) .0048 < .0001 (diagnosis)
.0638 (restaging)
Median 331 195 155
Average patient at CR (n = 55) 710 ± 162 421 ± 91 0.0858 (restaging)
P .0033
Median patient at CR 357 189
Correlation 43 of 55 patients at CR had reduced heparanase levels (78.2%)
Average patient at SD or TP (n = 9) 406 ± 55 508 ± 126
P .422
Median patient at SD or TP 217 253
Correlation 7 of 9 patients at SD or TP had elevated heparanase levels (77.8%)
CR, complete remission; SD, stable disease; TP, tumor progression.
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plasma levels of heparanase may assist in cancer diagnosis
and assessment of treatment efficiency.
Discussion
Heparanase activity has been traditionally correlated with
cell invasion associated with cancer metastasis, a conse-
quence of structural modifications that loosen the ECM
barrier [28–30]. More recently, heparanase upregulation
was documented in an increasing number of human carci-
nomas and hematological malignancies [7,9,11,31–33]. In
many cases, heparanase induction correlated with increased
tumor metastasis, vascular density, and shorter postopera-
tive survival rate, thus providing a strong clinical support for
the prometastatic and proangiogenic function of the enzyme
[7,9,10]. In addition to the well-studied catalytic feature of the
enzyme, heparanase was noted to exert biological functions
apparently independent of its enzymatic activity. This feature
requires heparanase secretion and is thought to be mediated
by as yet unidentified heparanase receptor. Thus, active and
inactive heparanase secreted by tumor cells or the tumor
microenvironment may exert local and systemic effects and
is the subject of anticancer drug development programs
[34,35]. We have recently reported the development of an
Table 2. Heparanase Levels in the Plasma of Patients with Hodgkin’s Disease.
HD Patients (n = 19) Heparanase
At Diagnosis (pg/ml) At Restaging (pg/ml) Normal (pg/ml)
Overall average 1019 ± 334 588 ± 173 163 ± 18
P (diagnosis vs restaging) .035 < .0001 (diagnosis)
0.0085 (restaging)
Median 433 259 155
Average patient at CR (n = 16) 1104 ± 390 586 ± 195 0.013 (restaging)
P (diagnosis vs restaging) .033
Median patient at CR 455 342
Correlation 13 of 16 patients at CR had reduced heparanase levels (81.3%)
CR, complete remission.
Figure 3. Elevated levels of heparanase in HD. Plasma samples of pediatric patients with HD were obtained at (n) diagnosis and at ( ) restaging following
chemotherapy. Heparanase levels were quantified for the (A) entire group (n = 19), (B) patients that were diagnosed to undergo CR (n = 16), and (C) patients that
exhibit disease progression. (D) Heparanase levels at (n) diagnosis and (5) restaging are shown for each individual patient.
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ELISA method capable of quantifying heparanase levels
in urine samples [19]. Here, we extended the utility of the
ELISA method and demonstrate that it can also be success-
fully applied to quantify heparanase in plasma. Heparanase
levels were significantly elevated in plasma obtained from
pediatric cancer patients. Few cases exhibited exceptionally
high levels of heparanase levels that decreased following
treatment to levels still relatively high (i.e., Figure 2D, no. 17;
Figure 3D, no. 2). Clinical aspects related to cases exhib-
iting high versus low levels of heparanase are currently
under intense analysis. Importantly, heparanase levels in
the plasma closely reflect the patients’ status following
anticancer treatment. Thus, heparanase levels were mark-
edly decreased in most patients undergoing remission, but
remained stable or slightly elevated in patients that re-
sponded poorly to treatment and exhibited TP (Table 1 and
Figure 2), suggesting that plasma heparanase originates
primarily from tumor cells, although minor contribution by im-
mune cells and platelets cannot be excluded. The correlation
between plasma heparanase levels and patient’s outcome
was evident for the entire study group (Figure 2) and for
the more homogenous group of HD patients (Table 2 and
Figure 3), revealing, for the first time, a possible involvement
of heparanase in this malignancy. Heparanase enzymatic
activity was noted in several types of hematopoietic cells,
including neutrophils, monocytes, megakaryocytes, and ac-
tivated lymphocytes [36–39], actively participating in their
extravasation during inflammation [5], and modulating cellu-
lar adhesion [40,41]. Elevated levels of heparanase were
found in leukemias, predominantly in cells of the myeloid
lineage [31], possibly involving single nucleotide polymor-
phism [42]. Interestingly, elevation of heparanase levels cor-
related with enhanced tissue factor expression in blasts
collected from acute leukemia patients [43], induction that
appears to require heparanase secretion and to be medi-
ated by the p38 signaling pathway [43]. This and other re-
ports describing signal transduction initiation by extracellular
heparanase [40,44–46] clearly depict the duality of secreted
heparanase, functioning as an enzyme and as a signaling
molecule, and the potential clinical significance of monitoring
extracellular heparanase levels. Furthermore, heparanase
elevation was also noted, for the first time, in the plasma of
sarcoma patients (Table 3 and Figure 4), an observation that
was further confirmed by immunostaining (Figure 5). In some
cases, staining of heparanase was clearly evident in invasive
cancer cells (Figure 5C), in agreement with a similar locali-
zation pattern noted in carcinomas [7], and the role of hepa-
ranase in cancer cell invasion and metastasis [8,9]. Thus,
heparanase elevation appears to be common for hemato-
logical and solid malignancies, including sarcomas, making it
Table 3. Heparanase Levels in the Plasma of Sarcoma Patients.
Sarcoma Patients (n = 15) Heparanase
At Diagnosis (pg/ml) At Restaging (pg/ml) Normal (pg/ml)
Overall average 324 ± 44 258 ± 65 163 ± 18
P (diagnosis vs restaging) .2107 .0023 (diagnosis)
.2293 (restaging)
Median 246 163 155
Average of patients at CR (n = 13) 342 ± 49 198 ± 37 0.4285 (restaging)
P (diagnosis vs restaging) .009
Median of patients at CR 308 140
Correlation 10 of 13 patients at CR had reduced heparanase levels (77%)
CR, complete remission.
Figure 4. Elevation of heparanase levels in sarcomas. Heparanase levels in the plasma of pediatric sarcoma patients (n = 15) are shown for each individual patient
at (n) diagnosis and (5) restaging. CR, complete remission; TP, tumor progression.
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a potential diagnostic and prognostic marker. The ELISA
method and the ability to quantify heparanase in urine [19]
and plasma are the first steps toward validating its signifi-
cance as a tumor marker.
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